FINAL YEAR B.PHARM. SEMESTER-VII (2011 COURSE) : SUMMER - 2018

SUBJECT: Dosage Form Design IV

Time: 02.00 PM TO 05.00 PM Day Saturday S-2018-3978 28/04/2018 Date Max. Marks: 80 **N.B.:** Q.No.1 and Q.No.5 are COMPULSORY. Out of the remaining questions 1) attempt ANY TWO questions from each section. 2) Answers to both the sections should be written in **SEPARATE** answer books. 3) Draw neat and labeled diagram WHEREVER necessary. 4) Figures to the right indicate FULL marks. SECTION - I Q.1 Attempt ANY FIVE of the following: (10)Explain how CDDS are superior to sustained release formulations? b) Draw neat diagram of ocusert system. What are compudose subdermal implants? c) d) Explain Brandt model in CDDS. Give the significance of fillers in silicon elastomers. e) f) What are Nitroder systems? g) Draw a neat diagram of Alzet osmotic pump. **Q.2** a) Classify activated modulated DDS and discuss iontophoretically activated (08) DDS. Discuss designing of matrix diffusion controlled DDS. b) (07)**Q.3** Explain how hydrodynamic diffusion layer influences release profiles of (08) b) Discuss mechanistic approach for release profiles of drug from membrane (07) permeation DDS. Write notes on ANY THREE: **Q.4** (15)Pennkinetic systems. b) Dynamics of GIT and its influence on drug release. c) Feedback regulated DDS. d) Mechanism of drug release from matrix DDS. Consideration of GI tansit in oral DDS. **SECTION-II** Answer **ANY FIVE** of the following: (10)**Q.5** Differentiate between GMP and cGMP. a) Define retrospective validation. b) Explain instability due to moisture. c) Differentiate between OA and OC. d) Enumerate various IPOC tests in production of tablets. e) State any two duties of coordinator in GLP. f) State the importance of cleaning validation. g) Discuss GMP in relation to building facilities. (08)Q.6 b) Discuss various components of GLP. (07)Discuss process validation. Give the procedure for validation of an (08)**Q.7** a) autoclave. (07)Discuss documentation and its significance. b) Write notes on (ANY THREE): **Q.8** (15)ICH stability guidelines. a) Mix up and cross contamination. b) Concept of TQM. c) Evaluation of preservatives. d) Cleaning validation. e)